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Abstract
Objective: Acute bladder distension results in pressure ischemia, subse-
quent reperfusion injury, and ultimately damage to the detrusor. We hypoth-
esize that changes in pressure may be a key factor to damage resulting 
from over-distension and developed a pressure-guided distension model 
to evaluate cystometric changes.
Materials and Methods: Three groups of adult female Sprague Dawley 
rats (250 g) were used: a sham distended control group, a 3-day (3D) and 
7-day (7D) follow-up group after pressure-guided distension. Under pento-
barbital anesthesia, the urethra was clamped and saline was infused 
(0.04 mL/min) under continuous intravesical pressure monitoring. After 
reaching 120 cmH2O pressure, infusion was stopped and clamping was 
maintained for 30 minutes. For sham distension, all procedures except 
the saline infusion were done.
Results: There were no bladder ruptures during distension. Distension vol-
umes needed to achieve the fixed pressure were variable (1.68–2.90 mL), 
but mean distension volumes were similar between the 3D and 7D groups 
(2.1 ± 0.1 mL vs. 2.2 ± 0.3 mL). After distension, maximal cystometric capac-
ity and residual urine volume were increased at both time points. Voiding 
efficiencies were decreased significantly in both the 3D and 7D groups 
(p < 0.05) compared to controls. Maximal vesical pressure and bladder 
compliance showed no change before and after distension.
Conclusion: Our pressure-guided distension model exhibits cystometric 
characteristics of bladder decompensation. This model for the underactive 
bladder™ (UAB) may prove useful to further the development of targeted 
UAB™ treatments. [Tzu Chi Med J 2009;21(2):136–139]
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1. Introduction
In the field of urology, overactive bladder syndrome 
(OAB) is a common medical problem and a number 
of antimuscarinic drugs are globally available. Yet, 
the inverse condition, underactive bladder™ (UAB), 
remains below the radar of academic experts and 
the pharmaceutical industry [1] even though bother-
some symptoms and potential sequelae are signifi-
cant. Although physicians treat patients with UAB™, 
the lack of a consensus definition is problematic in 
terms of syndrome recognition and developing effica-
cious treatments. The presence of urinary retention, 
high residual urine volumes, and incomplete bladder 
emptying have all been used as criteria for defining 
the disorder. Some of the established causes of UAB 
include neurogenic, myogenic, aging and medication 
side effects [2]. Detrusor underactivity is the antith-
esis to the OAB; however, symptoms may overlap. 
Common OAB symptoms include urgency, frequency, 
nocturia, and incontinence that may be overflow, 
urge and/or stress. Some symptoms more commonly 
associated with the UAB include hesitancy, sensation 
of incomplete emptying, straining to void and recur-
rent infections [3,4].
An interesting hypothesis is that the natural his-
tory of disease progression is from OAB toward UAB 
(Zhonghong Guan, MD, State University of New York 
Downstate Medical School; personal communica-
tion). How can the OAB progress to UAB? Recent re-
search has demonstrated that in OAB, the bladder 
wall thickens in mass [5,6] and there is a rise in urine 
nerve growth factor levels [7–9]. Therefore, OAB may 
involve structural changes that may eventually lead 
to alteration of muscle and connective tissue struc-
ture and function that can result in impaired contrac-
tility. To understand UAB and its potential relationship 
to OAB and other urological conditions, defined and 
reproducible modeling of the UAB first needs to be 
established. In this study, we explored modeling UAB 
in a rat model that would allow us to study new ther-
apies for the UAB.
2. Materials and methods
All experiments were performed on mature female 
Sprague Dawley (SD) rats (250–300 g) in accordance 
with the requirements and recommendations in the 
Guide for the Care and the Use of Laboratory 
Animals. Three groups of adult female SD rats (250 g) 
were used (n = 4 in each group): a sham distended con-
trol group, a 3-day (3D) follow-up group and a 7-day 
(7D) follow-up group after pressure-guided distension.
Under pentobarbital anesthesia (30 mg/kg, i.p.), a 
PE-50 catheter was inserted via the urethra and con-
nected with a Y connector to an infusion pump and 
Grass polygraph. A non-traumatic clamp was applied 
to the distal urethra and saline was infused (0.04 mL/
min) under continuous intravesical pressure moni-
toring. After reaching 120 cmH2O pressure, the infu-
sion was stopped and clamping was maintained for 
30 minutes. Higher pressure resulted in bladder rup-
ture during model development. For sham disten-
sion, all procedures were done in the same manner 
without the saline infusion.
At 3 or 7 days following bladder sham or hydro-
distention, transurethral cystometrograms were per-
formed under urethane anesthesia (1.2 g/kg, s.c.). 
Cystometric parameters included pressure thresh-
old, maximal vesical pressure, maximal cystometric 
capacity, residual urine volume, voiding efficiency 
and bladder compliance. The rats were sacrificed 
and bladder tissues from base of bladder were snap 
frozen using 2-methylbutane pre-cooled in liquid ni-
trogen. Serial 10-μm cryostat sections were obtained. 
Microscopic analysis of the sections was conducted 
after hematoxylin and eosin staining.
Data are expressed as arithmetic mean of “n” 
number of experiments and the standard error of the 
mean was computed. Voiding efficiency was calculated 
by dividing voided volume by bladder capacity and is 
expressed as a percentage. The statistical significance 
was analyzed by one-way analysis of variance followed 
by Newman Keuls test where appropriate. A level of 
p < 0.05 was considered significant. For statistical cal-
culations, the Prism3 statistical and graphic program 
(Graphpad, San Diego, CA, USA) was used.
3. Results
There were no bladder ruptures during bladder dis-
tension. None of the rats died or developed a urinary 
tract infection. Distension volumes to achieve the fixed 
pressure were variable (1.68–2.90 mL), but mean dis-
tension volumes were similar between the 3D and 7D 
follow-up groups (2.1 ± 0.1 mL vs. 2.2 ± 0.3 mL) (Table 1).
After distension, maximal cystometric capacity and 
residual urine volume were increased at both 3 and 
7 day time points (p < 0.05). Voiding efficiencies were 
decreased significantly in both 3D (p < 0.05) and 7D 
groups (p < 0.05) compared to controls. Maximal vesi-
cal pressure and bladder compliance showed no change 
before and after distension (Table 1). Examination of 
bladder tissues revealed no significant inflammation 
between control and hydrodistended groups on his-
tology at 3 and 7 days after hydrodistension.
4. Discussion
Treatment options for the UAB include double void-
ing, straining to void, and indwelling or intermittent 
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catheterization. Standard pharmacotherapy includes 
the use of α-adrenergic blocker to reduce urethral 
outlet resistance and muscarinic agonists such as 
bethechanol. Misoprostol, cholinesterase inhibitor 
and cholinergic agents are potential treatment candi-
dates, but safety and lack of benefit is a concern 
[4,10]. Treating UAB with novel muscarinic receptor 
manipulation such as presynaptic M2 receptor an-
tagonists or postsynaptic allosteric receptor enhance-
ment may yield promising results. Prokinetics used 
in gastroenterology and smooth muscle ionotropic 
agents used in cardiology may also warrant careful 
consideration for UAB treatment. Neuromodulation 
and intravesical electrical stimulation have also been 
reported to be potentially beneficial in selective pa-
tients. Experimentally, we have been interested in 
the use of trophic factors such as insulin growth fac-
tor and nerve growth factor to improve muscle and 
nerve function in the lower urinary tract. Use of stem 
cells and regenerative medicine may allow the weak 
detrusor to improve contractility [11,12], and finally 
gene therapy to increase weak individual myosite’s 
contractility with SERCA gene therapy [13].
We have previously explored selective area UAB 
modeling using cryoinjury [11,12]. An acute invasive 
bladder injury model was elaborated in our lab by 
short intense cooling of the bladder muscle. Under 
our experimental conditions, the cryoinjured blad-
der smooth muscle exhibited reproducibly impaired 
contractile parameters such that it may be applied 
as a model of insufficiently functioning smooth mus-
cle. For example, cryoinjury may be applied for test-
ing of therapies to improve detrusor contractility 
such as tissue engineering. Similar cryoinjury mod-
els have been used to model myocardial necrosis 
and to test myoblast transplantation in injured heart 
muscles. Striated muscles have also been subjected 
to cryoinjury to evoke degraded muscle function 
[11,12]. One weakness of our model is that urody-
namic measurements were done under urethane an-
esthesia. Although we have not seen decreased 
voiding efficiency with anesthesia, micturition under 
anesthesia is not the same as awake and future stud-
ies should consider avoidance of anesthesia. Another 
advancement for future studies would be use of longer 
duration of distension at lower elevated pressure 
which may more mimic chronic urinary distension in 
the clinical setting.
Currently, detailed epidemiologic and market data 
are lacking for UAB. However, it is likely that a per-
centage of men and women currently using α-blockers 
are being treated for UAB [14]. However, the break-
down of these numbers is unknown. Muscarinic ago-
nists are not highly effective and have common side 
effects. It is possible that the market for UAB treat-
ments, if proven safe and efficacious, can potentially 
exceed industry expectations as antimuscarinics did 
for OAB syndrome in the late 1990s. The pharma-
ceutical and biotechnology industries that have a 
pipeline in urology and women’s health should con-
sider the UAB as a potential target condition for 
developing new treatments. Our study demonstrated 
urodynamic and physiological changes after disten-
sion. Saito and Miyagawa [15] previously noted that 
after acute distension of the rat bladder via urethral 
clamping, dysfunction related to hypoperfusion and 
partially caused by free radicals may have an impor-
tant role in bladder dysfunction during acute urinary 
retention.
The results of our study indicate that our pressure-
guided distension model exhibits cystometric char-
acteristics of bladder decompensation in short-term 
follow-up. Despite variability in maximal distension 
volume, when the bladder is clamped to sustain high 
pressure, voiding efficiency significantly decreased. 
Since the life span of a research rat is typically less 
than 2 years, a research duration of 3–7 days may 
suggest a clinical relevant duration of several months, 
with the limitation of extrapolating animal research 
to clinical conditions. More research is needed to 
further establish sound animal models of UAB in 
order to allow for accurate testing of potential thera-
peutic agents for the treatment of UAB. A refinement 
of our model may also be used to test the interesting 
hypothesis that the OAB may progress to UAB.
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